A new study has found that enzalutamide can improve outcomes for patients with metastatic castration-resistant prostate cancer and visceral metastases compared to placebo.
A new study has found that enzalutamide can improve outcomes for patients with metastatic castration-resistant prostate cancer and visceral metastases compared to placebo.